PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it. Resistance to cancer immunotherapy can be mediated by additional immune checkpoints. We hypothesized that co-...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Haiping, Ni, Haiqing, Zhang, Pan, Guo, Xiaoli, Wu, Min, Shen, Haoran, Wang, Jie, Wu, Weiwei, Wu, Zhihai, Ding, Jiazheng, Tang, Rong, Zhou, Shuaixiang, Chen, Bingliang, Yu, Michael, Jing, Hua, Liu, Junjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237984/
https://www.ncbi.nlm.nih.gov/pubmed/34239776
http://dx.doi.org/10.1080/2162402X.2021.1943180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237984/
https://www.ncbi.nlm.nih.gov/pubmed/34239776
http://dx.doi.org/10.1080/2162402X.2021.1943180

Ejemplares similares